Success Stories: A Research Fellow from China Secured EB-1A Approval Within 10 days, Thanks to Premium Processing and Our Team
Client’s Testimonial:
"Thank you so much everyone who worked on my green card application. I and my family appreciate all your help during the process.”
On December 31st, 2020, we received another EB-1A (Alien of Extraordinary Ability) approval for a Research Fellow in the Field of Pharmaceutical Science (Approval Notice).
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Research Fellow
Country of Origin: China
State of Residence at the Time of Filing: Maryland
Approval Notice Date: December 31st, 2020
Processing Time: 10 days (Premium Processing Requested)
Case Summary:
A research fellow contacted us to assist him in building an EB-1A (Alien of Extraordinary Ability) petition on his account. We initiated the evaluation of his provided credentials, and after a thorough assessment, we established that we could certainly get him EB-1A approval based on his strong academic and professional background which satisfies the prong.
We detailed his doctoral degree in pharmaceutical science and pursuing his research which focused on investigating issues related to the application of pharmaceutical science to the treatment of cancers and liver cirrhosis. His drug discovery and delivery research addresses some of our nation’s and the world’s most pressing issues, including the need for more effective and targeted therapeutics for the treatment of cancers and liver diseases.
We noted his research has been widely cited and his collective publications (16 peer-reviewed journal articles (2 first-authored) and 2 patent applications) have been cited 360 times. Such a high citation count places him in the top tier of publishing researchers. Also, he has not only achieved the results of his research, but his discoveries have also been cited by researchers in at least 34 countries, thereby demonstrating that these publications are widely relied upon in the field of pharmaceutical science. Furthermore, we mentioned that he has conducted 24 reviews for journals, signifying his active and actual participation as a critic of the work of other experts in this area.
Moreover, we added 5 recommendation letters signed by several other experts in the field, verifying our client’s significant presence in the field of pharmaceutical science here in the United States. One of whom stated that:
“[Our client’s] research thus provides a viable solution to this continuing research challenge. Importantly, his novel treatment delivery methods enable the precise targeting of tumors for the inhibition of cancerous cell growth.”
We had a pleasure working with our client and thanks to premium processing, he received his EB1A approval from USCIS in just 10 days. We sincerely thank him for trusting our team in representing his case.